CA
FDMT icon

Clearstead Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Clearstead Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40 Buy
+3
New +$29 ﹤0.01% 3508

Other funds holding FDMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Clearstead Advisors's FDMT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 3 shares worth $40. The stake represents ﹤0.01% of the portfolio and ranks #3508 among its holdings.

53 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Clearstead Advisors held 3 shares of 4D Molecular Therapeutics worth $40 as of Q2 2026.
  • 4D Molecular Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3508 holding.
  • 53 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.